'That's Huge, Folks': Amarin's Vascepa Cuts CV Risk By 25% On Top Of Statins
Cardiovascular outcomes data exceeded expectations for the fish oil pill, vindicating Amarin, which has fought long and hard for Vascepa's place in the CV disease prevention market. A filing based on REDUCE-IT is expected in early 2019.
You may also be interested in...
If the lengthy litigation history is any guide, Amgen regretted licensing its first product to a big pharma partner, probably because the product was so successful. For most first products, however, a big pharmaceutical collaboration can bring many benefits but the converse – self-commercialization of the first product – has far fewer positive historical connotations.
The court included its decision on Amarin’s ’s petition for a writ of certiorari among the single-line denials of nearly 200 appeals to consider decisions in civil litigation and convictions in criminal cases. However, Amarin still eyes curbing competition from omega-3 supplements.
Sales of the triglyceride-lowering medicine soared to $112.4m in the third quarter even before a label expansion that depends on the outcome of a vital US FDA advisory committee meeting on 14 November.